Remergon Efficacy in Major Depressive Episode: A Randomized, Double-Blind, Clomipramine-Controlled Study in 174 French Hospitalized Patients.

Some statistically significant and possibly clinically meaningful differences between mirtazapine and other antidepressive agents were found for the acute-phase treatment of major depression. Mirtazapine is likely to have a faster onset of action than SSRIs during the acute-phase treatment. Dropouts occur similarly in participants treated with mirtazapine and those treated with other antidepressants, although the adverse event profile of mirtazapine is unique.

show abstract

Mirtazapine versus other antidepressive agents for depression

Watanabe

Omori

Nakagawa

et al. 2011

Cochrane Database of Systematic Reviews

138

125

View full text Add to dashboard Cite

show abstract

Org 3770 versus amitriptyline: A 6‐week randomized double‐blind multicentre trial in hospitalized depressed patients

Zivkov¹,

Jongh²

1995

Human Psychopharmacology

View full text Add to dashboard Cite

Following a placebo washout period of 3-7 days, 251 hospitalized patients with a major depressive episode (DSM I11 and RDC criteria) were treated with either Org 3770 (20-60 mg/day) or amitnptyline (75-225 mg/day) for six consecutive weeks in this randomized, double-blind, multicentre study. Forty-one patients (19 Org 3770,22 amitriptyline) withdrew before completion of the 6-week active treatment period. In both groups, the main reason for withdrawal was lack of efficacy. However, fewer patients in the Org 3770 group than in the amitriptyline group withdrew as a result of adverse events (one and three patients, respectively). The severity of depressive symptoms and general psychopathology, as assessed by HPRSD (total and factors) and BPRS scales, improved to the same extent after 6 weeks' treatment with Org 3770 and amitriptyline. Similar improvement in global functioning, as assessed by GAS scale, was observed in both treatment groups. There were no statistically significant differences between the two treatments on all scales used. Dry mouth and sweating were reported significantly more often in the amitriptyline group. Other adverse events, such as constipation, dizziness, tremor and muscle weakness, occurred more frequently in the amitriptyline-treated patients as well. The results of this study indicate that Org 3770 has similar antidepressant efficacy to amitriptyline and a more favourable tolerability profile in patients with major depression.

show abstract

Double-blind study of mirtazapine and placebo in hospitalized patients with major depression

Vartiainen

Leìnonen

1994

European Neuropsychopharmacology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Remergon Efficacy in Major Depressive Episode: A Randomized, Double-Blind, Clomipramine-Controlled Study in 174 French Hospitalized Patients.

Cited by 3 publications

References 0 publications

Mirtazapine versus other antidepressive agents for depression

Mirtazapine versus other antidepressive agents for depression

Org 3770 versus amitriptyline: A 6‐week randomized double‐blind multicentre trial in hospitalized depressed patients

Double-blind study of mirtazapine and placebo in hospitalized patients with major depression

Contact Info

Product

Resources

About